Genomic approaches to identifying targets for treating β hemoglobinopathies.

BMC Med Genomics · 2015 · PMC4517356 · PMID 26215470

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In a phase II study ( NCT00773890 ), an oral P-selectin blocker used chronically lowered plasma sVCAM and showed a trend toward improving microvascular flow [ 107 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.